Cutaneous and ocular toxicology · 2025
Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahesh Rathod, Das K Anjana, Thomas Christy, Kotakonda Sudha Rani, Maheshwari Kadari, Undela Krishna
Аннотация
OBJECTIVE: This study aimed to assess the potential risk of Bullous pemphigoid (BP) associated with antidiabetic agents, antimicrobials, diuretics, immune checkpoint inhibitors, and biological agents.
RESEARCH DESIGN AND METHODS: A retrospective pharmacovigilance data analysis was conducted using the FDA Adverse Event Reporting System (FAERS) between Q1/2004 and Q3/2024. Disproportionality analyses, viz. Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Information Component (IC) were performed to identify signals of BP. Additionally, a literature review of case reports of BP was conducted in PubMed, Google Scholar, and Scopus.
RESULTS: Disproportionality analysis identified 61 signals, and the following drugs exhibited the highest number of BP case associations: metformin (596 cases), vildagliptin (406 cases), nivolumab (376 cases), and furosemide (301 cases). Strong statistical correlation for signals was observed for vildagliptin [PRR = 295.8, LB (lower bound) ROR = 287.2, IC025 = 7.5], dapsone [PRR = 20.7, LBROR = 14.4, IC025 = 3.4], furosemide [PRR = 7.2, LBROR = 6.4, IC025 = 2.6], and nivolumab [PRR = 31.5, LBROR = 28.5, IC025 = 4.6]. These findings were supported by 106 identified case reports of BP.
CONCLUSION: This study suggests a strong statistical correlation between vildagliptin, dapsone, furosemide, nivolumab, and the development of BP.
RESEARCH DESIGN AND METHODS: A retrospective pharmacovigilance data analysis was conducted using the FDA Adverse Event Reporting System (FAERS) between Q1/2004 and Q3/2024. Disproportionality analyses, viz. Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Information Component (IC) were performed to identify signals of BP. Additionally, a literature review of case reports of BP was conducted in PubMed, Google Scholar, and Scopus.
RESULTS: Disproportionality analysis identified 61 signals, and the following drugs exhibited the highest number of BP case associations: metformin (596 cases), vildagliptin (406 cases), nivolumab (376 cases), and furosemide (301 cases). Strong statistical correlation for signals was observed for vildagliptin [PRR = 295.8, LB (lower bound) ROR = 287.2, IC025 = 7.5], dapsone [PRR = 20.7, LBROR = 14.4, IC025 = 3.4], furosemide [PRR = 7.2, LBROR = 6.4, IC025 = 2.6], and nivolumab [PRR = 31.5, LBROR = 28.5, IC025 = 4.6]. These findings were supported by 106 identified case reports of BP.
CONCLUSION: This study suggests a strong statistical correlation between vildagliptin, dapsone, furosemide, nivolumab, and the development of BP.